Webinar – Amyotrophic Lateral Sclerosis (ALS)

As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.

AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.

AMCP launched the metabolic health thought leadership program to empower payers to shift from siloed treatment to holistic, root-cause-focused metabolic health management—redefining roles in benefit design and population outcomes—starting immediately with the new ADA 2026 CGM expansions that are reshaping coverage and access.